Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance

Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance

<b>Background:</b> Olaparib and niraparib are poly (ADP-ribose) polymerase inhibitors (PARPi) used primarily for the treatment of ovarian cancer. While both drugs have demonstrated efficacy in clinical trials, their safety profiles, particularly in real-world clinical settings, remain to...

Full description

Saved in:
Bibliographic Details
Main Authors: Desirèe Speranza, Fausto Omero, Vincenzo Cianci, Mariapia Marafioti, Carla Infurna, Patrizia Carroccio, Edoardo Spina, Maria Antonietta Barbieri, Emanuela Esposito, Nicola Silvestris, Mariacarmela Santarpia
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Pharmaceuticals
Subjects:
olaparib
niraparib
EudraVigilance
pharmacovigilance
PARP inhibitors
real-world data
Online Access:https://www.mdpi.com/1424-8247/18/4/528
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1424-8247/18/4/528

Similar Items